Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia A
Status:
Completed
Trial end date:
2009-02-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the pharmacokinetic parameters and safety of Advate
rAHF-PFM versus Recombinate rAHF in well described previously treated patients with severe
hemophilia A (factor VIII level < 1%).